Eric DELPY

Dr. Eric DELPY

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2021 in Marine Drugs
Verified
Journal Article
Open access
PDF file
FBFareeha Batool
Fareeha Batool
EDEric DELPY
Eric DELPY
ZFZAL Franck
ZAL Franck
LELeize-Zal Elisabeth
Leize-Zal Elisabeth
Olivier HuckOlivier Huck
Olivier Huck
Oxygen (O2) is indispensable for aerobic respiration and cellular metabolism. In case of injury, reactive oxygen species are produced, causing oxidative stress, which triggers cell damaging chemical mediators leading to ischemic reperfusion injuries (IRI). Sufficient tissue oxygenation is necessary for optimal wound healing. In this context, several hemoglobin-based oxygen carriers have been developed and tested, especially as graft preservatives for transplant procedures. However, most of the commercially available O2 carriers increase oxidative stress and show some adverse effects. Interestingly, the hemoglobin derived from the marine lugworm Arenicola marina (M101) has been presented as an efficient therapeutic O2 carrier with potential anti-inflammatory, anti-bacterial, and antioxidant properties. Furthermore, it has demonstrated promise as a supplement to conventional organ preservatives by reducing IRI. This review summarizes the properties and various applications of M101. M101 is an innovative oxygen carrier with several beneficial therapeutic properties, and further research must be carried out to determine its efficacy in the management of different pathologies.

1 August 2021 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
HÖHayriye Özçelik
Hayriye Özçelik
FBFareeha Batool
Fareeha Batool
MCMaïwenn Corre
Maïwenn Corre
AGAlexandre Garlaschelli
Alexandre Garlaschelli
GCGuillaume Conzatti
Guillaume Conzatti
Olivier HuckOlivier Huck
Olivier Huck

1 September 2016 in Journal of Pharmacological and Toxicological Methods
Verified
Journal Article
Open access
HPHelen Prior
Helen Prior
ABAnna Bottomley
Anna Bottomley
PCPascal Champéroux
Pascal Champéroux
JCJason Cordes
Jason Cordes
EDEric DELPY
Eric DELPY
KCKathryn Chapman
Kathryn Chapman
The Safety Pharmacology Society (SPS) and National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs) conducted a survey and workshop in 2015 to define current industry practices relating to housing of non-rodents during telemetry recordings in safety pharmacology and toxicology studies. The aim was to share experiences, canvas opinion on the study procedures/designs that could be used and explore the barriers to social housing. Thirty-nine sites, either running studies (Sponsors or Contract Research Organisations, CROs) and/or outsourcing work responded to the survey (51% from Europe; 41% from USA). During safety pharmacology studies, 84, 67 and 100% of respondents socially house dogs, minipigs and non-human primates (NHPs) respectively on non-recording days. However, on recording days 20, 20 and 33% of respondents socially house the animals, respectively. The main barriers for social housing were limitations in the recording equipment used, study design and animal temperament/activity. During toxicology studies, 94, 100 and 100% of respondents socially house dogs, minipigs and NHPs respectively on non-recording days. However, on recording days 31, 25 and 50% of respondents socially house the animals, respectively. The main barriers for social housing were risk of damage to and limitations in the recording equipment used, food consumption recording and temperament/activity of the animals. Although the majority of the industry does not yet socially house animals during telemetry recordings in safety pharmacology and toxicology studies, there is support to implement this refinement. Continued discussions, sharing of best practice and data from companies already socially housing, combined with technology improvements and investments in infrastructure are required to maintain the forward momentum of this refinement across the industry.

24 December 2021 in Artificial Organs
Verified
Journal Article
Closed access
PDF file
YMYannick Le Meur
Yannick Le Meur
EDEric DELPY
Eric DELPY
FRFelix Renard
Felix Renard
Thierry HauetThierry Hauet
Thierry Hauet
LBLionel Badet
Lionel Badet
BBBenoit Barrou
Benoit Barrou

Verified
Journal Article
Open access
PDF file
NFNjikem ASONG FONTEM
Njikem ASONG FONTEM
Arnau Panisello-RosellóArnau Panisello-Roselló
Arnau Panisello-Roselló
ALAlexandre Lopez
Alexandre Lopez
KIKatsunori Imai
Katsunori Imai
ZFZAL Franck
ZAL Franck
René  AdamRené Adam
René Adam
The combined impact of an increasing demand for liver transplantation and a growing incidence of nonalcoholic liver disease has provided the impetus for the development of innovative strategies to preserve steatotic livers. A natural oxygen carrier, HEMO2life®, which contains M101 that is extracted from a marine invertebrate, has been used for static cold storage (SCS) and has shown superior results in organ preservation. A total of 36 livers were procured from obese Zucker rats and randomly divided into three groups, i.e., control, SCS-24H and SCS-24H + M101 (M101 at 1 g/L), mimicking the gold standard of organ preservation. Ex situ machine perfusion for 2 h was used to evaluate the quality of the livers. Perfusates were sampled for functional assessment, biochemical analysis and subsequent biopsies were performed for assessment of ischemia-reperfusion markers. Transaminases, GDH and lactate levels at the end of reperfusion were significantly lower in the group preserved with M101 (p < 0.05). Protection from reactive oxygen species (low MDA and higher production of NO2-NO3) and less inflammation (HMGB1) were also observed in this group (p < 0.05). Bcl-1 and caspase-3 were higher in the SCS-24H group (p < 0.05) and presented more histological damage than those preserved with HEMO2life®. These data demonstrate, for the first time, that the addition of HEMO2life® to the preservation solution significantly protects steatotic livers during SCS by decreasing reperfusion injury and improving graft function.

6 May 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
ABAnne‐Marie Bétat
Anne‐Marie Bétat
ADAnnie DELAUNOIS
Annie DELAUNOIS
EDEric DELPY
Eric DELPY
MLMathilde Loiseau
Mathilde Loiseau
AMAnne Maurin
Anne Maurin
JVJean‐Pierre Valentin
Jean‐Pierre Valentin